Eisai publishes additional detailed analyses from lecanemab phase 2b study March 31, 2023 08:00 Non Regulatory Read more
New lecanemab-data to be presented at the AD/PD™ 2023 conference March 23, 2023 08:00 Non Regulatory Read more
Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal March 20, 2023 00:30 Non Regulatory Read more
U.S. Veterans’ Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer’s disease March 13, 2023 20:30 Non Regulatory Read more
FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease and grants Priority Review March 6, 2023 00:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 28, 2023 February 28, 2023 18:00 Regulatory Read more
Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration February 28, 2023 00:30 Non Regulatory Read more
The Nomination Committee’s proposal for the election of Board members and Chairman of the Board in BioArctic AB February 6, 2023 08:30 Regulatory Read more
European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease January 27, 2023 00:30 Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2022 on February 3 at 9.30 a.m. CET January 25, 2023 08:30 Non Regulatory Read more
BioArctic’s Chairman of the Board Wenche Rolfsen declines re-election January 19, 2023 09:50 Regulatory Read more
BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in Japan January 16, 2023 01:30 Regulatory Read more
BioArctic’s partner Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in the EU January 11, 2023 00:30 Regulatory Read more
BioArctic’s partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease January 7, 2023 05:30 Non Regulatory Read more
FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer’s disease January 6, 2023 20:30 Regulatory Read more
